Why mitochondria keep appearing in longevity conversations
Mitochondria turn food and oxygen into ATP, the energy currency every cell spends. They also do something less obvious: they participate in signalling that governs cell survival, inflammation and how cells respond to stress. As they lose efficiency with age, the consequences ripple outward into muscle function, metabolic health and the diseases that cluster with ageing.
That is the mainstream view, not a fringe one — mitochondrial dysfunction appears on essentially every serious list of ageing hallmarks. It is also the reason a small group of compounds that act on mitochondria attracts so much attention, and why the gap between a real target and a real benefit matters so much here.
Because mitochondrial dysfunction is genuinely associated with nearly every age-related disease, it is easy to assume that anything improving mitochondrial function in a dish or a mouse will improve a person's health. Almost nothing has cleared that bar. This guide walks through the three compounds readers ask about most, in order of how much human evidence sits behind each.
How to judge a mitochondrial claim
Five questions sort most of the noise out:
- Does it have a defined target? Cardiolipin binding, AMPK signalling and NAD+ substrate availability are three very different things. Vague 'supports cellular energy' language usually means no target is known.
- What is the best human evidence? Countdown: large randomised trial, small randomised trial, uncontrolled case series, animal only, cell only. Be sceptical of anything that stops before the word randomised.
- Does the measured effect matter to a person? ATP production in cultured cells is a biomarker. Walking distance, strength and glucose control are outcomes. The two are not interchangeable.
- Does the compound reach the tissue it is meant to affect? A mitochondrial peptide injected into the blood must survive, distribute and enter cells. Most product listings never address this.
- Who profits from you believing it? This is not cynicism, it is pattern recognition. The compounds with the thinnest evidence often have the loudest sellers.
SS-31 (elamipretide): the most elegant mechanism, the most disappointing trials
Elamipretide is a four-amino-acid peptide designed to concentrate inside mitochondria and bind cardiolipin, the phospholipid that anchors and organises the proteins of the electron transport chain. The logic is unusually tidy: if energy production fails because the inner membrane's architecture breaks down, a molecule that holds that architecture together should help. It works on membrane structure rather than on a receptor.
In cells and animals it does what the design predicts — improved electron transport efficiency, restored ATP production in damaged mitochondria, reduced oxidative damage. That earned it the interest of serious academic groups and a well-funded clinical programme.
The human results have been the hard part. The pivotal trial in primary mitochondrial myopathy did not meet its primary endpoint. A trial in progeria missed its endpoints too. A small trial in Barth syndrome reported improvements on several secondary functional measures, but it was not powered to show a change in the disease's clinical course, and regulators have not approved the drug. The pattern — beautiful mechanism, encouraging early signals, missed pivotal endpoints — is the single most instructive thing about this compound.
Elamipretide is the mitochondria field's cautionary tale: it reached late-stage human testing, which almost no research peptide does, and it still could not demonstrate clinical benefit.
In the trials, dosing was 40 mg per day by subcutaneous injection in patients with serious mitochondrial disease, delivered with specialist monitoring. There is no approved dose, no approved product and no evidence base for using it as a general vitality compound. The peptide sold online borrows the reputation of the research, not the results.
MOTS-c: a peptide encoded inside your mitochondria
MOTS-c was the discovery that changed how mitochondria are described — from power plants to signalling organelles. It is sixteen amino acids long and encoded not in the nuclear genome but within mitochondrial DNA itself, which is why the field calls it a mitochondrial-derived peptide.
It behaves as a metabolic messenger: it travels between the mitochondrion, the cytoplasm and the nucleus, influences the folate–methionine cycle and the antioxidant response, and activates AMPK, the cell's central energy sensor. In mice, administering it improves glucose handling, reduces fat accumulation and increases exercise capacity in some studies. Circulating levels in people change with fasting, training and age.
Everything after the word mice is where the evidence stops. Human work on MOTS-c is observational: levels correlate with metabolic and training status. There is no published trial of giving the peptide to humans, no pharmacokinetic data and no dose-finding study.
MOTS-c has a real mechanism and no human pharmacology. Anyone quoting a human dose for it is inventing one.
That is not a reason to dismiss it as a research molecule — it is a genuinely interesting one. It is a reason not to inject it. Note also that much of what MOTS-c does in animals overlaps with what exercise does, which is where the human evidence for this pathway actually lives.
NAD+: not a peptide, and the most confusing evidence base here
NAD+ belongs in this guide because it is bought and discussed alongside these compounds, and because it is the one readers most often assume has been figured out. It is not a peptide. It is a dinucleotide coenzyme that every living cell depends on.
It has two jobs that matter. In metabolism it carries electrons in the redox reactions that make ATP. As a signalling substrate it is consumed by enzymes including sirtuins, PARPs and CD38, which use it to regulate DNA repair, stress responses and inflammation. NAD+ levels fall with age and in metabolic disease, and the falling levels limit the activity of those enzymes. That is a real, well-documented piece of biology.
The precursor route
Oral nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are precursors the body converts into NAD+. They do what they claim at the level of the marker: trials consistently show that supplementing raises NAD+ in blood and tissue. That replication is worth something.
Clinical benefit is much weaker ground. A randomised trial in older adults reported lower systolic blood pressure and improved arterial stiffness with NR. A randomised trial of NMN in postmenopausal women with prediabetes reported improved muscle insulin sensitivity. Both findings are interesting and both came from small studies. No trial has yet shown that raising NAD+ changes hard outcomes — disease incidence, physical function or lifespan — and several trials are industry-supported, which is worth weighing when the effect sizes are modest.
The infusion route
Intravenous NAD+ is offered in clinics for energy, recovery, neurological complaints and addiction. There are no controlled trials supporting those claims, and the infusion itself is not benign: it is commonly associated with nausea, chest tightness, flushing and lightheadedness, and infusing quickly can drop blood pressure. The dosing schedules used in clinics are not derived from dose-finding studies, because for these purposes those studies do not exist.
What is actually established
| Claim | Status | | --- | --- | | NAD+ declines with age and in metabolic disease | Well established | | Oral precursors raise NAD+ levels | Established in short randomised trials | | NAD+ levels predict health outcomes | Correlational, not causal | | Precursors improve disease outcomes or lifespan in humans | Not demonstrated | | IV NAD+ delivers the benefits clinics advertise | Unsupported by controlled evidence |
What the three have in common
All three target real biology, and all three are sold in ways that outrun their evidence. The differences are instructive rather than cosmetic:
- SS-31 has the most human exposure and the weakest human results. It failed its pivotal endpoints after reaching phase 3.
- MOTS-c has convincing animal data and no human data of any kind.
- NAD+ has reliable target engagement — the marker moves — and unproven clinical benefit. Only this one has repeatedly replicated human trials, and none of those trials answered the question people care about.
None of the three has an established human dose that a reader can act on outside a monitored trial or prescription. All three are supplied as research-use-only material or clinic infusions with no product approval behind them.
The unglamorous part that does have evidence
If the goal is mitochondrial function, the interventions with the strongest human evidence are not sold in vials. Endurance and resistance training increase mitochondrial content and function through pathways that overlap directly with the ones described above, and they do so with outcome data — strength, aerobic capacity, glucose control — rather than marker data. Sleep, energy balance, not smoking and managing blood-sugar disorders all show up consistently. Certain prescription medicines used in specific mitochondrial diseases have real outcome data in those diseases, under medical supervision.
That is not a platitude. It is the correct comparison: when a peptide is sold on mitochondrial biology, the honest benchmark is the biology you can already access.
Safety and the limits of this page
- Do not self-administer research peptides. Material sold as research-use-only is unverified for identity, purity and sterility, which matters more for injected compounds that affect cellular energy metabolism than it does for anything taken topically.
- SS-31 and MOTS-c have no human safety database for injection. Chronic activation of energy-sensing pathways is a theoretical concern, not a documented one — and not a reassuring situation either.
- NAD+ infusions cause real reactions (nausea, chest tightness, flushing, blood-pressure drops), and anyone on blood-pressure medication, pregnant or managing heart disease should treat them as medical procedures rather than wellness treatments.
- Interactions matter. Several common medicines influence mitochondrial function, and layering an unregulated compound on top removes any ability to tell what is doing what.
- This page is educational. It is not medical advice, it is not a recommendation to use any compound, and it does not replace a conversation with a physician who knows your history. See our disclaimer for the full position.
If you want the underlying detail on any single compound, the dossiers for elamipretide, MOTS-c and NAD+ cover their mechanisms, evidence and safety notes in more depth.